Silexion Therapeutics (SLXN) spikes as investors react to mid-May clinical-trial milestones and fresh financing

By: Quiver PriceTracker

Posted: 1 day, 22 hours ago / May 20, 2026 5:37 p.m. UTC

SLXN

Silexion Therapeutics Corp (SLXN) is up 76.8% today. Here is some analysis on what might have caused this price movement.

Analysis: The move appears tied to a burst of mid-May company updates highlighting progress toward starting its Phase 2/3 program for SIL204 in locally advanced pancreatic cancer, alongside a warrant-exercise financing that strengthened near-term liquidity. In a micro-cap biotech, this kind of clinical/regulatory momentum can also trigger momentum trading; this could be because the stock’s low float amplified buying pressure.

Details:

The company highlighted that Israeli regulators approved initiation of its Phase 2/3 clinical trial for SIL204 and reiterated timing expectations for trial start in Q2 2026.

The company also disclosed that a Clinical Trial Application was submitted in Germany via the EU clinical-trials framework, positioning the program for multi-country European execution.

Earlier in the week, the company announced positive preliminary preclinical immuno-oncology findings, including increased MHC-I expression following SIL204 treatment in KRAS-mutated cancer cells, supporting potential future combination strategies.

The company also announced an inducement transaction for immediate warrant exercises at a reduced price that was expected to generate roughly $1 million in gross proceeds for working capital and general corporate purposes.

Sources:

Silexion Therapeutics (press releases), SEC EDGAR, StreetInsider

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

$SLXN Hedge Fund Activity

We have seen 2 institutional investors add shares of $SLXN stock to their portfolio, and 2 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

TWO SIGMA SECURITIES, LLC added 11,657 shares (+inf%) to their portfolio in Q1 2026, for an estimated $14,920
CITADEL ADVISORS LLC added 8,721 shares (+71.5%) to their portfolio in Q1 2026, for an estimated $11,162
UBS GROUP AG removed 1,174 shares (-69.4%) from their portfolio in Q1 2026, for an estimated $1,502
SBI SECURITIES CO., LTD. removed 1,040 shares (-98.1%) from their portfolio in Q1 2026, for an estimated $1,331
PFLUG KOORY, LLC added 0 shares (+0.0%) to their portfolio in Q1 2026, for an estimated $0
MONTAG A & ASSOCIATES INC added 0 shares (+0.0%) to their portfolio in Q1 2026, for an estimated $0
JONES FINANCIAL COMPANIES LLLP added 0 shares (+0.0%) to their portfolio in Q1 2026, for an estimated $0

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.